We examined the brains of 266 patients with prion disease (PrionD) and found that 46 patients (17%) had Alzheimer disease (AD)Ylike changes. To explore potential mechanistic links between PrionD and AD, we exposed human brain aggregates (BrnAggs) to a brain homogenate from a patient with sporadic Creutzfeldt-Jakob disease and found that neurons in human BrnAggs produced many A-amyloid (AA; AA42) inclusions, whereas uninfected control-exposed human BrnAggs did not. Western blot analysis of 20 pooled CreutzfeldtJakob diseaseYinfected BrnAggs verified AA42 levels higher than those in controls. We next examined the CA1 region of the hippocampus from 14 patients with PrionD and found that 5 patients had low levels of scrapie-associated prion protein (PrP Sc ), many AA42 intraneuronal inclusions, low apolipoprotein E-4 (APOE-4), and no significant nerve cell loss. Seven patients had high levels of PrP Sc , low AA42, high APOE-4, and 40% nerve cell loss, suggesting that APOE-4 and PrP Sc together cause neuron loss in PrionD. There were also increased levels of hyperphosphorylated tau protein (HT) and HT-positive neuropil threads and neuron bodies in both PrionD and AD groups. The brains of 6 age-matched control patients without dementia did not contain AA42 deposits; however, there were rare HT-positive threads in 5 controls, and 2 controls had few HT-positive nerve cell bodies. We conclude that PrionD may trigger biochemical changes similar to those triggered by AD and suggest that PrionD is a disease involving PrP Sc , AA42, APOE-4, and abnormal tau.
INTRODUCTION
As part of our collaborative studies with Dr. Stanley B. Prusiner on the biology and treatment of prion disease (PrionD) and other neurodegenerative diseases, we have collected and analyzed the brains of 266 patients with PrionD, including 240 patients with sporadic Creutzfeldt-Jakob disease (sCJD), 19 patients with familial Creutzfeldt-Jakob disease (fCJD), and 7 patients with Gerstmann-Sträussler-Scheinker disease (GSS). Prion disease and Alzheimer disease (AD) may share certain pathogenic mechanisms. In 1998, Hainfellner et al (1) reported a 10.9% overlap of AD in 110 cases of Creutzfeldt-Jakob disease (CJD). They concluded that the coexistence of AD-type pathology with CJD most probably represented coincidental events. On the other hand, Lauren et al (2) reported that cellular prion protein (PrP C ) is a high-affinity receptor of A-amyloid (AA; AA42) oligomers in AD and that binding to PrP C mediates the deleterious effects of AA42. Parkin et al (3) showed that PrP C inhibits the A-secretase (BACE-1) cleavage of amyloid precursor protein (AAPP), which is the first step in the formation of AA40 and AA42. Kovacs et al (4) reported that fCJD associated with the E200K PRNP mutation forms a complex proteinopathy consisting of scrapie-associated prion protein (PrP Sc ), tau, >-synuclein, and deposition of AA. They also reported that AA deposits may be detected in sCJD.
Here, we investigated how the replacement of PrP C with PrP Sc may promote AA42 production and how PrionD might induce AD-like pathologic changes in some patients. First, we determined the number of definite AD or early (incipient) AD cases (defined by the presence of extracellular AA42 neuritic plaques) among our 266 cases of PrionD. Next, we wanted to know whether intracellular AA42 peptide is formed in neurons and glial cells in the absence of AA42 plaque formation in PrionD. Because abnormal hyperphosphorylated tau protein (HT) and AA42 neuritic plaques define AD, we wanted to know whether HT is formed in the brains of patients with PrionD. We report the concomitant occurrence of neuropathologic findings consistent with PrionD and AD, suggesting that AA peptides and abnormal tau are induced in PrionD. For controls, we used 6 age-matched patients with no neurologic diseases. Other control data were obtained from the literature and included reports of examinations of the brains of a large number of nondemented patients (5Y9).
To test the interaction of PrP C , PrP Sc , AA42, and abnormal tau, we used an in vitro cell model of brain aggregates (BrnAggs). After 20 days in culture, these BrnAggs were found to contain mature neurons with dendrites, axons, and synapses, and other cellular CNS elements, including astrocytes, oligodendrocytes, and microglia. In a previous study in mice, we showed that the susceptibility of BrnAggs to prions was similar to the susceptibility of BrnAggs to in vivo disease and that BrnAggs provided a clear view of the distribution of PrP Sc in the plasma membrane and subcellular structures (10) .
MATERIALS AND METHODS

Patients
We examined 266 consecutive cases of PrionD in the Neuropathology Research Laboratory of the Department of Pathology at University of California San Francisco (UCSF). We also studied 127 AD cases from the files of the Neuropathology Unit. As controls, we examined the brains of 6 agematched (3 men and 3 women; aged 54Y69 years) nondemented individuals.
Estimates of Gross Brain Abnormalities
Brains were characterized by degree of atrophy (i.e., none, mild, moderate, or severe) based on brain weight and visual inspection of the cerebral cortex. Atrophy of the hippocampus was scored as positive if the inferior horn was dilated and the size of the hippocampus was smaller than normal on visual inspection. Protrusion of the lateral ventricles (0.2Y1.5 cm) into the frontal lobe in a coronal section taken immediately rostral to the temporal poles qualified as mild hydrocephalus; extensive rounding and dilation of the anterior horn, body, and inferior horn of the lateral ventricle and third ventricle were considered as severe hydrocephalus. Depigmentation of the locus coeruleus (LC) and substantia nigra was also evaluated.
Histoblot Technique
Cryostat sections of brain samples were prepared from fresh frozen tissue. Coronal (full and half) sections of fresh frozen human brains were cut (25 Km thick) with a Leica Cryopolycut microtome (International Medical Equipment Inc, San Marcos, CA). Routine frozen sections of the brain (1Y2 Â 3 inches) were cut (10 Km thick) with a Microm HM505 cryostat (Carl Zeiss, Thornwood, NY) and pressed onto the nitrocellulose membrane. The resulting histoblots were treated with proteinase K to eliminate PrP C and with 3 mol/L of guanidinium to denature PrP Sc for immunohistochemical staining of proteaseresistant PrP Sc , which is diagnostic of PrionD (11, 12) . The same technique, without the denaturation step, was used to stain for protease-resistant AA peptides characteristic of AD (13) . The histologic diagnoses of incipient and definite AD were established by semiquantitative estimates of the number of neocortical AA42 neuritic plaques using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria (14) .
Neurohistology and Molecular Biology
Brain samples were fixed in 10% buffered formalin and embedded in paraffin using standard procedures. Degree of vacuolation as a percentage of gray matter area, pattern, and laminar distribution of vacuolation (assessed with hematoxylinand-eosin stain) were estimated. Hematoxylin-and-eosinYstained tissue was also evaluated for the presence of other lesions such as infarcts and Lewy bodies. Fresh frozen and formalin-fixed tissues were sent to the National Prion Disease Surveillance Center for genetic testing of PRNP gene mutations and codon 129 polymorphism and for Western blot analysis of PrP Sc phenotypes.
Immunohistochemistry of Human Brains
Brain sections were cut (8 Km thick), deparaffinized, and processed for immunohistochemistry. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol. Nonspecific antibody binding sites were blocked with 10% normal horse serum. For detection of human PrP Sc , we used mouse 3F4 antibody (1:1000) and HuM-P antibody conjugated to horseradish peroxidase (1:10000) (gifts from Dr. Stanley B. Prusiner, UCSF, San Francisco, CA). The intensity of PrP Sc immunostaining was scored semiquantitatively as mild (1+), moderate (2+), moderately severe (3+), or severe (4+).
Abnormal HT was detected with mouse AT8 antibody (1:250), which is specific for phosphorylated paired helical filamentous tau Ser202/Thr205 (cat no. MN1020B; Life Technologies, Carlsbad, CA). We stained AA42 with 4G8 monoclonal antibody (1:500) specific for AA42 at epitopes 12 to 24 (cat no. SIG-39220; BioLegend Co [formerly Covance Antibody Products], San Diego, CA). Cortical Lewy bodies were detected with mouse monoclonal >-synuclein antibody (1:250) (LB509, cat no. Ab27766; Abcam, Cambridge, MA). Sections to be stained with 3F4 and AT8 antibodies were subjected to hydrolytic autoclaving for 10 minutes at 121-C in citrate buffer. Sections to be stained with 4G8 monoclonal antibody were immersed in formic acid for 5 minutes. Tissue stained with >-synuclein antibodies was not pretreated. All sections were incubated with primary antibodies overnight at room temperature and with biotinylated horse anti-mouse secondary antibody (1:200) (cat no. BA-2000; Vector Laboratories Inc, Burlingame, CA) for 30 minutes at room temperature. Antibody binding was detected using a Vectastain ABC kit (PK-4000) and visualized with 3,3 ¶-diaminobenzidine (DAB peroxidase substrate kit SK-4100; Vector Laboratories Inc).
Scoring Cortical HT
Hyperphosphorylated tau protein immunopositivity in the LC/raphe nuclei (RN) of nerve cell bodies, neuropil threads, and dystrophic neurites was scored (from 0 to 4+) and multiplied by the total area of the LC/RN involved. Total HT load in the medial temporal lobe (MTL) was estimated by multiplying HT score by the extent of affected layers in the cortex (Â1 if HT was found in 2Y3 layers; Â2 if HT was found in all 6 layers). Final scores were multiplied by the number of regions in the MTL in which HT was found, which varied from 1 to 6 depending on the number of affected regions (hippocampus, subiculum, presubiculum, entorhinal cortex, transentorhinal cortex, and inferior temporal cortex).
Brain Aggregates
Mouse BrnAggs (Mo BrnAggs) were prepared from E15 day gestation embryos obtained from pregnant transgenic (tau-P301L)4510 mice (gift from Dr. George Carlson, McLaughlin Research Institute, Great Falls, MT). Fetal brains were genotyped by polymerase chain reaction for the presence of tau(P301L), and the calmodulin kinase II promoter system was used to construct transgenic mice (15, 16) . Human fetal brain tissues at 15 to 17 weeks of gestation were obtained from Advanced Bioscience Resources Inc (Alameda, CA) and used to prepare cell cultures of human BrnAggs (Hu BrnAggs). All experiments involving human brain tissue were performed at Biohazard Safety Level 3 in accordance with our Biologic Use Authorization.
Brain aggregates were prepared as previously described (10) . Briefly, mouse and human brain cells were dissociated through 2 nylon meshes. After 2 washes with DMEM H21 containing glucose (12 g/L), fungizone (2.5 mg/L), and gentamicin (50 mg/L), dissociated neural cells were resuspended in a modified growth medium DMEM H21 containing glucose (6 g/L), gentamicin (50 mg/L), fungizone (2.5 mg/L), and 10% fetal bovine serum at a density of 1 Â 10 7 cells/mL. Four milliliters of cells was placed in 25-mL Delong flasks and kept at constant rotation (37-C, 10% CO 2 ). The next day, 1 mL of exchange medium consisting of DMEM H21 supplemented with glucose 6 g/L, gentamicin 50 mg/L, and 15% fetal bovine serum was added to the flask. After 2 to 3 days, rotated BrnAggs were transferred to 50-mL Delong flasks to which 5 mL of exchange medium was added, for a total of 10 mL. The exchange medium was refreshed every 2 to 3 days by removing 5 mL of conditioned medium and replacing it with 5 mL of fresh exchange medium. For Mo BrnAggs, after 6 to 8 days in culture, the growing and fusing BrnAggs were transferred to a 24-well culture plate, which was also maintained in constant rotation. For Hu BrnAggs, this process was performed at approximately 12 to 14 days. The medium was changed every 2 to 3 days by discarding 500 KL of conditioned medium and replacing it with an equal volume of exchange medium.
Exposure of BrnAggs to Prions
After 15 days in culture, Mo BrnAggs were exposed for 10 days to Rocky Mountain Laboratories prions (1:50 dilution) derived from scrapie-infected CD1 mouse brains. After Sc by Western blot analysis using antiYprion protein (PrP) HuM-P horseradish peroxidase (1:10000) antibody, AA1Y42 (AA42)Yspecific antibody (1:500, SIG-39142; BioLegend Co [formerly Covance Antibody Products]), and antitau oligomeric antibody (1:1000, ABN454; Millipore, Temecula, CA) overnight at room temperature.
For detection of AA42, 5 Hu BrnAggs exposed to sCJD prions and 2 control BrnAggs not exposed to prions were fixed with 4% paraformaldehyde for 1 hour. The BrnAggs were embedded in paraffin, cut (8 Km) , and mounted on glass slides. After deparaffinization, they were submerged in formic acid for 5 minutes for antigen retrieval and incubated with AA1Y42 (AA42)Yspecific antibody (1:500) overnight at room temperature. The secondary antibody, goat anti-mouse Alexa Fluor 488 (A11029; Life Technologies) conjugated to fluorescein isothiocyanate, was applied for 2 hours. The slides were coverslipped in mounting medium containing DAPI (H-1200; Vector Laboratories Inc), analyzed, and photographed with a Leica DM IRB fluorescence microscope.
Quantification of Western Blot Analysis
Levels of AA were quantified with BioQuant Life Science software (Bioquant Image Analysis Corp, Nashville, TN).
Statistical Analysis
Statistical analysis of human brain weights and Mo BrnAggs was performed using Student t-test. Chi-squared test was used to compare the distribution of deaths (by age group) and the prevalence of PrionD and AD. One-way analysis of variance with multiple comparisons was used to compare mean ages in the Prion-only, AD-only, and Prion-AD groups.
RESULTS
Overlap of PrionD and AZ
For CERAD staging of AD, we examined multiple brain regions, including the hippocampus, entorhinal cortex, transentorhinal cortex, inferior temporal cortex, lateral frontal cortex areas 45 and 46, lateral parietal cortex areas 39 and 40, cingulate cortex area 24, and medial occipital cortex (14, 17) . Of the 266 PrionD cases reviewed for the study, 46 cases (17%) showed both PrP Sc and extracellular AA42 plaques and were designated as the Prion-AD group (Tables 1, 2 ). This group included 41 sCJD cases, 4 fCJD cases, and 1 GSS case. In 18 of 46 Prion-AD cases, a sufficient number of AA42 plaques were detected in all cerebral cortical regions and in some subcortical regions to qualify for ''definite'' AD by CERAD criteria. In the remaining 28 Prion-AD cases, the number of AA42 plaques was insufficient to make a diagnosis of definite AD; therefore, we designated them as ''incipient AD.'' The 220 cases with PrP Sc but no detectable AA42 plaques were designated as ''Prion-only'' cases.
Epidemiology
In the Prion-AD group, the mean T SD age at death was 67.2 T 8.8 years (n = 45 available ages) ( Fig. 1B ; Tables 1, 2 ). The mean T SD age at death in the Prion-AD group was significantly older than that in the Prion-only group (62.8 T 10.8 years; n = 209 available ages) ( Table 2 ) and significantly younger than that in the 127 AD-only group seen at UCSF (76.8 T 11.1 years) ( Fig. 1B ; Table 2 ) (p = 0.005 and p G 0.001, respectively; analysis of variance controlled for multiple comparisons) .
The female-to-male ratio was calculated for each group because the AD literature indicates that women have an increased risk for AD (18, 19) . Among our 127 cases of AD-only, the female-to-male ratio was 1.35, which is consistent with the literature ( Fig. 1D ; Table 2B ). Among 44 Prion-AD cases (the sex of 2 cases was not reported), the female-to-male ratio was 1.32, which was similar to that in AD-only cases. In contrast, Prion-only cases were predominantly male (106 men and 95 women), and the female-to-male ratio was 0.90 (Table 2B) . We combined the number of women and men from the Prion-only group with the number of women and men from the Prion-AD group to test whether the predominance of men in Prion-only cases was caused by a shift of women from the Prion-only group to the Prion-AD group. The totals (120 women and 125 men) yielded a slight male predominance with a female-tomale ratio of 0.96 (Table 2B ). In the Prion-AD group, more women were older than 65 years, and slightly more men than women were aged between 50 and 64 years (Fig. 1B) . These data are similar to findings showing that AD is more common in older women than in men.
PrP
Sc and AA42 Plaque Distribution
In most patients, PrP Sc was distributed either in all layers of the cortex or in deep layers 4 to 6. Rarely was the distribution of PrP Sc found in superficial layers 1 to 3. For cases in which PrP Sc was deposited in deeper cortical layers, such as an 81-year-old woman who was near the end of the age distribution for the Prion-AD group ( Fig. 2A) , AA42 plaques tended to be distributed in superficial layers 1 to 3 (Fig. 2B) . In another case of a 53-year-old woman who was at the beginning of the Prion-AD age distribution, PrP Sc staining was confined to layers 5 and 6 in the lateral frontal cortex (Fig. 2C) and AA42 plaques were located in layer 1 (Fig. 2D) . In the parietal cortex of the same patient, PrP
Sc accumulated in all 6 cortical layers (Fig. 2E) , and AA42-positive plaques were found in cortical layers 1 to 5 (Fig. 2F ). This suggests that AA42 plaques are first formed in layer 1 of the cerebral cortex and subsequently progress in order from layers 2 through 6. To determine whether AA42 peptide formed and accumulated in neurons in vivo in the absence of extracellular AA42 plaques, we performed AA42 immunohistochemistry of the CA1 region of the hippocampus and the entorhinal cortex in 14 recent Prion-only cases (13 sCJD and 1 GSS). Neuron counts in the CA1 region were determined by counting neurons in 5 consecutive microscopic fields (10Â). We identified 3 groups of Prion-only cases (Table 3 ). In the first group, Cases 1 to 5 had abundant intracellular AA42 in the CA1 region (Fig. 3B) . The neurons of the CA1 region appeared normal in size and shape, and the mean number of neurons was 188, with only Case 1 showing a decrease in neurons to 131 ( Fig. 3B ; Table 3 ). Furthermore, AA42 seemed to fill a few glial cells that were identified based on their small size compared with the size of neurons (Fig. 3B) . In the second group, Cases 6 to 12 showed accumulation of AA42 in less than 5% of neurons in the CA1 region (Fig. 3D) . In some of those cells (neuron or glial), AA42 seemed to fill the cytoplasm, giving them a rounded appearance, although adjacent neurons appeared normal in size and contained only a small amount of AA42 (Fig. 3D) . The mean number of neurons was 127, which verified our visual impression of nerve cell loss ( Table 3 ). The mean number (188) of neurons found in Cases 1 to 5 and the mean number (127) of neurons found in Cases 6 to 12 were significantly different (p = 0.01, t-test). In the third group, Cases 13 and 14 had low AA42 levels and no nerve cell loss, showing a mean number of 212 neurons (Table 3) . These data suggest the role of another factor (in addition to AA42 and PrP Sc ) in determining neuron death.
Nerve Cell Loss Correlates With Apolipoprotein E-4
A factor that is more likely to cause nerve cell death is apolipoprotein E-4 (APOE-4). The APOE-4 allele is associated with increased risk and earlier onset of AD; APOE-3/3 allele is associated with a significantly lower risk of AD, and APOE-2 allele is associated with a decreased risk of AD and delayed onset of AD (20Y22). Apolipoprotein E is normally expressed in astrocytes but not in neurons (23) . Under conditions of stress, such as in mice treated with kainic acid, many hippocampal neurons express APOE-4. In another study, the expression of APOE-4 was associated with neuronal apoptosis (24) .
We used APOE-4Yspecific antibodies to stain the CA1 region in 14 Prion-only cases ( Table 3 ). The percentage of nerve cell bodies in the CA1 region containing AA42 and APOE-4 was quantified. Three markedly different results were obtained (Table 3) . First, Cases 1 to 5 had low APOE-4 content in CA1 neurons and relatively few punctate APOE-4 deposits in the neuropil (Fig. 3E ), which were associated with very little loss of CA1 neurons (Table 3) . Second, Cases 6 to 12 had high intracellular neuronal APOE-4 content (Fig. 3F) , which was associated with significant CA1 neuron loss and many APOE-4 deposits in the neuropil ( Fig. 3F; Table 3 ). Third, Cases 13 and 14 contained very low amounts of APOE-4 and no associated nerve cell loss (Table 3) . Accumulation of APOE-4 in neurons, resulting in apoptosis, was reflected by the large numbers of shrunken neurons with degenerating nuclei (Fig. 3F, arrows) . We conclude that nerve cell loss was related to increased levels of APOE-4 and not to AA42.
sCJD(VV2) Induces AA in Hu BrnAggs
Human BrnAggs were derived from the brain of a 16-week human fetus, which did not contain extracellular AA42 plaques of AD. Starting from the second day in culture, BrnAggs were exposed to a normal human brain homogenate, exposed to a human sCJD(VV2) brain homogenate, or not exposed to any brain substance (None). The BrnAggs were terminated at 35 days. We pooled groups of 20 Hu BrnAggs to test each condition by Western blot analysis. An increase in AA42 was visibly recognizable in BrnAggs exposed to sCJD(VV2) but not in BrnAggs exposed to a normal brain homogenate or in BrnAggs not exposed to any brain substance (None) (Fig. 4A) . Densitometry of AA bands using BioQuant Life Science software produced densities of 542, The number of patients in (B) differs from that in (A) because of the absence of information on the sex of some patients. *Mutations found: E200K (7), V210I (3), R208H (1), octapeptide insertion (3), and not available (2). †Mutations found: P102L (1), A117V (2), and Q217R (2).
1,506, and 450 for None, sCJD(VV2), and Normal Brain, respectively (Fig. 4B) , indicating that sCJD(VV2) induced a 3.35-fold increase in AA compared with a normal brain homogenate and a 2.78-fold increase in AA compared with no treatment. To confirm infection with sCJD(VV2), we treated the samples with proteinase K and subjected them to Western blot analysis. Prion proteinYspecific antibodies yielded the 3 signature proteinase KYresistant bands in Hu BrnAggs exposed to sCJD(VV2) but none in Hu BrnAggs exposed to a normal brain homogenate or in Hu BrnAggs not exposed to brain tissue (None) (Fig. 4A) . In a preliminary study, Hu BrnAggs were exposed to sCJD(VV2) for immunohistochemical localization of AA42. Prion exposure was begun on Day 2 in culture and was terminated at 35 days. Human BrnAggs were fixed with 4% paraformaldehyde. Immunostaining using anti-AA antibodies showed that all 5 of the Hu BrnAggs exposed to sCJD(VV2) were filled with large and small AA42 aggregates in nerve cell bodies and in the neuropil (data were not shown because a normal age-matched human brain homogenate from a nondemented patient was not used as control). When examined by double labeling (AA42 and the lysosomal marker cathepsin D), AA42 deposits seemed to be located mainly in the cytosol and only minimally in lysosomes. In contrast, BrnAggs not exposed to prions showed little or no AA42. These observations suggest that sCJD prions induced intraneuronal AA42 peptide accumulation relatively rapidly and without formation of extracellular AA42 plaques.
sCJD(VV2) Induces HT in Hu BrnAggs
Untreated Hu BrnAggs produced large bands of tau (between 35 and 50 kDa) (Fig. 4C ). Exposure to a normal brain homogenate produced smaller bands (between 35 and 45 kDa) and 2 very weak bands (È60 and 9100 kDa) (Fig. 4C) . Exposure to sCJD(VV2) produced bands between 40 and 50 kDa and strong bands (from 60 to 9100 kDa) of phosphorylated tau (Fig. 4C) .
In another preliminary study, we made BrnAggs from transgenic mice expressing human mutated tau(P301L). These mouse tau(P301L) BrnAggs spontaneously form small numbers of neurons containing HT in nerve cell bodies and dendrites. When Mo BrnAggs were exposed to an AA42-containing homogenate from a transgenic (HuAPP 695 SWE)2576 mouse, the number of neurons containing abnormal tau increased approximately 2-fold. In contrast, when tau(P301L) BrnAggs were exposed to a brain homogenate from a wild-type mouse infected with Rocky Mountain Laboratories scrapie prions containing PrP Sc , the number of neurons and their processes containing abnormal tau increased 10-fold. These results were reproduced in triplicate. The findings argue that exposure to AA42 and PrP Sc increases the levels of HT inclusions in 
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Comparison of AA42, APOE-4, and nerve cell loss in 5 regions (10Â) of the CA1 region of the hippocampus. Apolipoprotein E-4 load is the number of APOE-4Ypositive neurons in the CA1 region multiplied by APOE-4 staining intensity (0, none; 1, mild; 2, moderate; 3, severe). The t-test value for APOE-4 load in Cases 1 to 5 and Cases 6 to 12 is 0.07.
*PRNP genotype and PrP Sc phenotype. EC, entorhinal cortex; F, female; M, male; MM, methionine-methionine; MV, methionine-valine; nd, not determined; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum; VV, valine-valine. tau(P301L) BrnAggs. We did not use normal age-matched human brain homogenate controls in these studies, which is why we classified them as preliminary (data not shown).
HT in 6 Age-Matched Controls
The brains of 6 patients (aged 48Y69 years and with no history of dementia) were used as controls. One control had no AT8-positive HT (Fig. 5A) . Three controls had varying amounts of AT8 positivity consisting of small numbers of HT bearing neuropil threads grouped into clusters (Figs. 5BYD,  arrows) . Increasing amounts of HT-positive neuropil threads mixed with intensely stained individual nerve cell bodies occurring in clusters were seen in 2 other controls (Figs. 5E, F) . All HT existed as small single or multiple disconnected and patchy HT deposits in the presubiculum, entorhinal cortex, or transentorhinal cortex.
HT in the MTL of PrionD and AD Cases
Unlike controls in which abnormal tau staining was focal, HT staining of MTL in CJD-only (19 cases), GSS-only (1 case), CJD-AD (7 cases), and AD-only (5 cases) was continuous or multifocal and extended from the entorhinal cortex into the transentorhinal cortex (Figs. 6C, F) . Cases of CJD-only and CJD-AD showed strong positive and continuous staining in layers 1 and 2 of the entorhinal cortex and transentorhinal cortex (Fig. 6B) . Lower-intensity HT staining was also present in neuropil threads and neurons in deeper layers of the entorhinal cortex in CJD-only cases. Cases of CJD-AD showed intense immunostaining in the superficial layers and less intense immunostaining in the deeper layers of the entorhinal cortex (Figs. 6E, F) . In AD-only cases, many HT threads and nerve cell bodies were stained (Figs. 6H, I ). The most intense staining occurred in the GSS-only case (Figs. 6K,  L) . In all of the groups, the presubiculum showed little HT staining. The hippocampal CA1 region and subiculum were intensely stained in CJD-AD and AD-only cases, whereas the GSS-only case had staining in portions of the CA1 region and the subiculum.
HT Quantification
The density and distribution of AT8-immunopositive HT were estimated in the LC/RN of the pons and in the MTL in 36 cases (Fig. 7) . These cases included 20 Prion-only (19 sCJD and 1 GSS), 7 CJD-AD, 5 AD-only, and 4 ''other'' (3 cases of TDP-43 encephalopathy and 1 case of dementia lacking distinctive pathology) cases. We compared HT loads by estimating the intensity of HT staining multiplied by the area stained in the LC/RN and MTL. The highest densities of HT were found in the MTL, and the lowest densities of HT were found in the LC/ RN (Figs. 7A, B) . The densities of HT in the MTL were significantly higher in the AD-only and CJD-AD groups compared with the Prion-only group (t-test, p G 0.001; Fig. 7B ). In Prion-only cases, a score of 1 or 2 represents the presence of any focal HT staining in the entorhinal cortex; therefore, it may represent nonspecific HT staining. A score of 3 or more represents a continuous deposition of disease-related HT in the entorhinal cortex and transentorhinal cortex (Fig. 6C) . The sole score of 48 occurred in the GSS case (Fig. 7A) .
DISCUSSION
In examining 266 cases of PrionD, we found that 46 patients (17%) also had AD and AD-like changes. In a previous study, Hainfellner et al (1) looked at 110 cases of CJD using anti-PrP, anti-AA, and anti-tau immunostaining plus the Bielschowsky silver method to examine a single neocortical block of brain tissue. They found a 10.9% overlap of PrionD and AD and proposed that AD and prion pathology are coincidental events (1). Like Hainfellner et al (1), we also used anti-PrP, anti-AA, and anti-tau immunostaining plus the Bielschowsky silver method, but we examined multiple neocortical areas.
The yearly incidence of sCJD, which accounts for approximately 90% of PrionD cases, is 1 to 2 cases per million (25) . The incidence of PrionD is similar to its prevalence because patients usually die within 1 year of diagnosis. The yearly incidence of AD may be as high as approximately 150,000 cases per million (26) , but patients may live 10 years or longer; thus, the prevalence is much greater than the incidence. We could not find adequate data on the prevalence of AD by age to allow us to determine whether our findings were coincidental or mechanistic, but the proportion of Prion-AD cases found in both studies strongly suggests that the large size (25%Y30%) of the preclinical and definite AD populations overlaps with many populations, including the population of PrionD cases. Because we found large quantities of AA inside neurons in Prion-AD cases, our results are consistent with the concepts that the mechanism of AD in PrionD starts with PrP Sc stimulation of AA synthesis and that its accumulation inside neurons is not relevant to the proportion of preclinical and definite AD. This hypothesis is supported by several factors linking PrionD and AD.
The age of patients in the Prion-AD group led us to think that PrionD might induce AD or AD-like changes. In our series, the findings of concomitant Prion-AD changes began abruptly at about age 50 years and seemed to end just as abruptly at age 84 years, except for 1 outlier who died at age 93 years. The older age (84 years) of Prion-AD cases coincides with the end of the Prion-only group. By contrast, AA-associated pathology in AD-only cases continued to increase in the brain until the last AD case died at the age of approximately 100 years (7, 27) . The implication of these data is that AD does not induce PrionD, whereas PrionD induces AD and AD-like pathology. These observations led us to look further to see whether we could identify mechanisms by which PrionD could cause or accelerate the onset of AD in susceptible patients.
Other factors that link PrionD to AD are the formation and neuronal accumulation of PrP Sc , which increases levels of AA (28) , and the subsequent formation and accumulation of APOE-4 in neurons ( Fig. 3; Table 3 ). Both events also occur in AD-only cases without PrP Sc stimulation. We saw low levels of PrP Sc , high intraneuronal levels of AA, and low levels of intraneuronal APOE-4 in patients with PrionD who died without apparent nerve cell loss in the CA1 region of the hippocampus. We saw high levels of PrP Sc , low levels of intracellular AA, and the transition of APOE-4 to high levels in patients who demonstrated nerve cell loss (Table 3 ). The study by Umeda et al (29) supports the role of AA oligomers in causing nerve cell death through an endoplasmic reticulum stress mechanism; however, they did not mention APOE-4 activation, a factor that most likely links AA pathology to apoptosis of nerve cells (24) . Apolipoprotein E-4 binds tightly to AA42 to clear it from neurons (30) . As a result, soluble oligomeric AA levels are increased by APOE-4 (31). We found that concomitant changes in PrionD and AD occurred in patients aged between 50 and 85 yearsVthe time when APOE-4 (a known risk factor for AD) (32, 33) and neprilysin-> (34) (the predominant degrading enzyme of AA40 and AA42) (35) exert their maximal effects on the development of AD (36) .
Apolipoprotein E alleles are not a risk factor for PrionD (37), but APOE-4 contributes to nerve cell death in patients with PrionD. In our Prion-only cases, Cases 1 to 5 had low
PrP
Sc levels, high intraneuronal levels of AA42, low numbers of neurons expressing APOE-4, and little neuronal loss in the CA1 region (Table 3) . Prion-only cases (Cases 6Y12) that had high PrP Sc levels, low AA42 levels, and high APOE-4 levels had a 40% mean loss of CA1 neurons. In Cases 6 to 12, we also saw punctate APOE-4 immunostaining in the neuropil between nerve cell bodiesVfindings that were not observed in Cases 1 to 5. We believe that the neuropil APOE-4 resulted from nerve cell death, releasing APOE-4 into extracellular space. Neuronal death was an apoptotic event based on the number of shrunken neurons with fragmented nuclei containing APOE-4 seen in the section (Fig. 3F) . Therefore, it seems that increasing PrP Sc levels triggers an increase in APOE-4. (B) Antibodies to AA peptide showed that exposure to sCJD(VV2) resulted in increased levels of AA in BrnAggs, whereas no treatment (None) and treatment with human brain homogenate (Normal Brain) did not. (C) Antibodies to tau protein showed that sCJD(VV2) was the only treatment that caused a large amount of phosphorylated tau (molecular mass 960 kDa) to be generated. The normal brain homogenate generated very small bands (60 and 9100 kDa). Molecular weights are indicated in each immunoblot. The sole exception to this pattern was Case 2 (Table 3) , a case of GSS associated with a 9-octapeptide repeat insertion in the PRNP gene. This patient had a 10-year history of tremors that progressed to a severe mental disorder during the last 2 years of life; 80% of his CA1 neurons contained AA42 peptide, and PrP Sc deposits were densely granular and associated with GSS plaques. Nerve cell loss was not identified in the CA1 region, although APOE-4 levels were not particularly low (Table 3) .
The literature indicates that homozygosity at codon 129 of the PRNP gene (either M/M or V/V) is associated with an increased risk of developing sCJD, iatrogenic CJD, or variant CJD (38Y40). In the German population, M/M homozygosity at codon 129 is a risk factor for early-onset AD, but not for late-onset AD (41) . In the Dutch population, the risk of developing early-onset AD is higher for V/V homozygotes than for M/M homozygotes (42). In our study, an overrepresentation of codon 129 homozygosity (84%) was found in the Prion-only and Prion-AD groups compared with the general US population (49%) ( Table 3) . However, the PrionD-AD association was not exclusively related to homozygosity because a small percentage of Prion-AD cases in our cohort were heterozygous (M/V).
Our results suggest that being female is a risk factor for the simultaneous occurrence of PrionD and AD. It has been reported that women have a 2-fold higher risk of developing AD than men. This increased risk has been attributed to the loss of estrogen after menopause (18, 19, 43) and to the fact that women tend to live longer than men (44) . In our Prion-AD cases, the female-to-male ratio was 1.32, which was similar to that in the AD-only group (1.35) but different from that in the Prion-only group (0.90). Because nearly all of our Prion-only cases died within less than 1 year of disease onset, the longevity of women was not an issue in Prion-AD cases. In contrast, the sex distribution associated with intracellular AA42 accumulation in the absence of AA42 plaques in our Prion-only cases was predominantly male (9 of 14 cases) ( Table 3 ). This observation suggests that the emergence of amyloid plaques of AD has a greater association with women. It is interesting that 3 of 4 MV Prion-AD cases were female ( Table 1) .
The second classic neuropathologic feature of AD is accumulation of HT. Several clinical studies have identified increased levels of total tau and phosphorylated tau in the cerebrospinal fluid of patients with CJD (45Y47). Our autopsy study seems to be the first to demonstrate increased amounts of abnormal tau (HT) and AA42 peptides on immunohistochemistry and biochemistry in Prion-only, Prion-AD, and AD-only cases versus ''other'' neurodegenerative disease cases, including TDP-43 encephalopathy and dementia lacking distinct histology (Fig. 7) . The highest levels of HT were present in the AD-only group, with progressively less HT in the Prion-AD and Prion-only groups. In the Prion-only group (Fig. 7) , 4 tau loads in the MTL were given a tau score of 1, which did not represent continuous tau immunostaining in the entorhinal cortex and transentorhinal cortex but represented HT staining that was similar to our 6 controls. The ''other'' group of neurodegenerative disease had the least HT score from 0 to 3. In summary, in some patients, PrionD induces pathology consistent with AD (increased number of extracellular AA42 plaques, increased intracellular AA42 peptide accumulation, and increased deposition of HT). Prion disease is able to induce AD changes but AD does not seem to induce PrionD. Thus, we propose that PrionD is a disorder of 4 aberrant protein conformers (i.e., PrP Sc , AA42, APOE-4, and HT) and that each of these proteins contributes to the pathogenesis of PrionD.
Does it matter whether PrionD induces or accelerates AD? It certainly did not matter to the patient who died of PrionD within a year. A better understanding of the combined effects of PrP Sc , AA42, APOE-4, and HT on PrionD, however, may provide potential targets for prion therapy. More importantly, understanding how PrionD can incite AD-like changes may lead to the discovery of additional triggers and clues to control the growing epidemic of AD.
